Evaluation of risk for development of myeloproliferative disorders, myelodysplastic syndromes, or acute leukemias with long-term eculizumab therapy in paroxysmal nocturnal hemoglobinuria (PNH) patients

被引：0
|
作者：
Schubert, J.
Young, N. S.
Luzzatto, L.
Brodsky, R. A.
Socie, G.
Rother, R. P.
Rollins, S. A.
Hillmen, P.
机构：
[1] Saarland Univ, Sch Med, Homburg, Germany
[2] NHLBI, Bethesda, MD 20892 USA
[3] Ist Toscano Tumori, Florence, Italy
[4] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[5] Hosp St Louis, Paris, France
[6] INSERM, Paris, France
[7] Alexion Pharmaceut Inc, Cheshire, CT USA
[8] Leeds Gen Infirm, Leeds, W Yorkshire, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7087
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Long-Term Efficacy and Safety of Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria and High Disease Burden: Real-World Data From Korea
    Kim, Jin Seok
    Jang, Jun Ho
    Jo, Deog-Yeon
    Ahn, Seo-Yeon
    Yoon, Sung-Soo
    Lee, Je-Hwan
    Kim, Sung-Hyun
    Choi, Chul Won
    Shin, Ho-Jin
    Kim, Min-Kyoung
    Lee, Jae Hoon
    Mun, Yeung-Chul
    Kong, Jee Hyun
    Hyun, BokJin
    Nam, HyunSun
    Kim, Eunhye
    Kwak, Min Joo
    Won, Yong Kyun
    Lee, Jong Wook
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2023, 38 (41) : 1 - 12
  • [42] Danicopan As Add-on Therapy to Ravulizumab or Eculizumab Versus Placebo in Patients with Paroxysmal Nocturnal Hemoglobinuria and Clinically Significant Extravascular Hemolysis: Phase 3 Long-Term Data
    Kulasekararaj, Austin
    Griffin, Morag
    Piatek, Caroline I.
    Shammo, Jamile
    Nishimura, Jun-Ichi
    Patriquin, Christopher J.
    Schrezenmeier, Hubert
    Gaya, Anna
    Patel, Yogesh
    Liu, Peng
    Filippov, Gleb
    De Fontbrune, Flore Sicre
    Risitano, Antonio M.
    Lee, Jong-Wook
    BLOOD, 2023, 142
  • [43] Danicopan As Add-on Therapy to Ravulizumab or Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: Long-Term Patient-Reported Outcomes from the Phase 3 ALPHA Trial
    Piatek, Caroline
    Lee, Jong Wook
    Griffin, Morag
    Nishimura, Jun-Ichi
    Patriquin, Christopher
    Schrezenmeier, Hubert
    Barcellini, Wilma
    Shammo, Jamile
    Gaya, Anna
    Mahdi, Mohammed
    Liu, Peng
    Myren, Karl-Johan
    Messali, Andrew
    de Fontbrune, Flore Sicre
    Panse, Jens
    Kulasekararaj, Austin G.
    BLOOD, 2024, 144 : 2693 - 2694
  • [44] Decreased CD55 and CD59 levels on granulocytes in myelodysplastic syndrome (MDS) and myeloproliferative disorders (MPDs): Potential pitfalls for paroxysmal nocturnal hemoglobinuria (PNH) assays
    Talwalkar, S. S.
    Brahmandam, A.
    Jorgensen, L. J.
    MODERN PATHOLOGY, 2008, 21 : 276A - 276A
  • [45] Long-term outcome of therapy-related myelodysplastic syndromes and acute myeloid leukemias arising in patients treated for lymphoma or breast cancer
    Milani, R.
    Zanni, M.
    Dodero, A.
    Spina, F.
    Testi, A.
    Tarella, C.
    Bernardi, M.
    Gallamini, A.
    Bandini, G.
    Benedetti, F.
    Gianni, A. M.
    Corradini, P.
    LEUKEMIA RESEARCH, 2007, 31 : S126 - S127
  • [46] Decreased CD55 and CD59 levels on granulocytes in myelodysplastic syndrome (MDS) and myeloproliferative disorders (MPDs): Potential pitfalls for paroxysmal nocturnal hemoglobinuria (PNH) assays
    Talwalkar, S. S.
    Brahmandam, A.
    Medeiros, L. J.
    Jorgensen, J. L.
    LABORATORY INVESTIGATION, 2008, 88 : 276A - 276A
  • [47] Long-term support of hematopoiesis by a single stem cell clone in patients with paroxysmal nocturnal hemoglobinuria
    Nishimura, J
    Hirota, T
    Kanakura, Y
    Machii, T
    Kageyama, T
    Doi, S
    Wada, H
    Masaoka, T
    Kanayama, Y
    Fujii, H
    Inoue, N
    Kuwayama, M
    Inoue, N
    Ohishi, K
    Kinoshita, T
    BLOOD, 2002, 99 (08) : 2748 - 2751
  • [48] Use of the oral complement factor B inhibitor iptacopan in patients (pts) with paroxysmal nocturnal hemoglobinuria (PNH) with persistent hemolysis despite anti-C5 therapy: long-term efficacy and safety after stopping eculizumab (ECU)
    Roth, A.
    Peffault de Latour, R.
    Soret, J.
    Frieri, C.
    Sicre de Fontbrune, F.
    Marano, L.
    Alashkar, F.
    Benajiba, L.
    Marotta, S.
    Kulmatycki, K.
    Nidamarthy, P. K.
    Fagan, N.
    Junge, G.
    Risitano, A. M.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 173 - 174
  • [49] Long-term outcome of therapy-related myelodysplastic syndromes and acute myeloid leukemias arising in patients treated for lymphoma or solid tumors.
    Milani, Raffaella
    Palmieri, Salvatore
    Zanni, Manuela
    Pollio, Filiberto
    Dodero, Anna
    Spina, Francesco
    Testi, Adele
    Tarella, Corrado
    Bernardi, Massimo
    Gallamini, Andrea
    Bandini, Giuseppe
    Benedetti, Fabio
    Ferrara, Felicetto
    Corradini, Paolo
    BLOOD, 2007, 110 (11) : 727A - 727A
  • [50] LONG-TERM EVOLUTION OF TYPE III ERYTHROCYTES DURING ECULIZUMAB TREATMENT IN PATIENTS WITH PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA
    Moncharmont, P.
    Barraco, F.
    Bernaud, J.
    Raffin, A.
    Michallet, M.
    Rigal, D.
    HAEMATOLOGICA, 2012, 97 : 574 - 575
12345